OSR Holdings Appoints Dr. Constance Höfer as Chief Scientific Officer
Rhea-AI Summary
OSR Holdings (NASDAQ: OSRH) has appointed Dr. Constance Höfer as its new Chief Scientific Officer (CSO). Dr. Höfer brings over 20 years of experience in drug development, specializing in oncology and immunology. She previously held leadership positions at Merck Healthcare, where she led global programs from preclinical to late-stage clinical development.
Dr. Höfer's extensive background includes senior roles at Sandoz Biopharmaceuticals, Priaxon AG, and Medigene AG, where she advanced therapeutic programs across various modalities including NBEs, NCEs, nucleotides, and viral and cell-based therapies. She holds a PhD in Pharmacology from the University of Newcastle and has expertise in clinical pharmacology and translational medicine.
The appointment aims to strengthen OSR Holdings' R&D capabilities and accelerate the development of breakthrough therapies. Dr. Höfer will oversee the company's scientific strategy, innovation pipeline, and focus on expanding its footprint in oncology and immunology.
Positive
- Appointment of highly experienced CSO with 20+ years in drug development
- Strong expertise in multiple therapeutic modalities and development stages
- Enhanced R&D leadership in oncology and immunology sectors
- Potential for improved clinical development and regulatory success rates
Negative
- None.
News Market Reaction – OSRH
On the day this news was published, OSRH declined 7.51%, reflecting a notable negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Dr. Höfer joins OSR Holdings from Merck Healthcare, where she led global programs spanning from preclinical to late-stage clinical development. Prior to Merck, she held senior leadership positions at Sandoz Biopharmaceuticals, Priaxon AG, and Medigene AG, playing a key role in advancing therapeutic programs across various modalities, including New Biological Entities (NBEs), New Chemical Entities (NCEs), nucleotides, and viral and cell-based therapies.
Regarding her new appointment, Dr. Höfer said "I am honored to join the distinguished team at OSR Holdings and eager to leverage my extensive drug development experience to advance novel therapies across multiple modalities and therapeutic areas. I look forward to collaborating with my colleagues to improve the lives of patients."
Coupled with her extensive industry experience and a PhD in Pharmacology from the University of Newcastle, Dr. Höfer has a strong foundation in clinical pharmacology and translational medicine, ensuring a seamless transition from early-stage research to successful clinical development.
"We are thrilled to welcome Constance to OSR Holdings. Her depth of experience and proven leadership in drug development will be instrumental in driving our scientific strategy forward," said Kuk Hyoun Hwang, CEO of OSR Holdings. "With her deep understanding of preclinical-to-clinical transition strategies and regulatory pathways, she will play a pivotal role in optimizing our pipeline and accelerating the development of breakthrough therapies for patients worldwide."
Dr. Höfer's appointment reinforces OSR Holdings' commitment to advancing cutting-edge therapeutic solutions and strengthening its R&D capabilities. Her expertise will enhance the company's ability to identify and develop promising drug candidates, streamline clinical development, and improve regulatory success rates. By leveraging her experience in biologics, small molecules, and other advanced therapeutic modalities, OSR Holdings aims to accelerate the translation of innovative research into clinical applications, expand its footprint in oncology and immunology, and drive long-term value for both patients and stakeholders.
About OSR Holdings, Inc.
OSR Holdings, Inc. (OSR) is a global healthcare company dedicated to advancing healthcare outcomes and improving the quality of life for people and their families. OSR aims to build and develop a robust portfolio of innovative and potentially transformative therapies and healthcare solutions. Its current operating businesses (through three wholly owned subsidiaries) include (i) developing oral immunotherapies for the treatment of cancer, (ii) developing design-augmented biologics for age-related and other degenerative diseases and (iii) neurovascular intervention medical device and systems distribution in
Contact
Email: ir@osr-holdings.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/osr-holdings-appoints-dr-constance-hofer-as-chief-scientific-officer-302410052.html
SOURCE OSR Holdings Inc.